RESEARCH ARTICLE

HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014

Amanda Häggblom1,2, Stefan Lindbäck3, Magnus Gisslén4, Leo Flamholc5, Bo Hejdeman6, Andreas Palmborg3, Amy Leval9, Eva Herweijer7, Sverrir Valgardsson3, Veronica Svedhem2,8*

1 Department of Infectious Diseases, County Council of Gävleborg, Gävle, Sweden, 2 Unit of Infectious diseases, Department of Medicine Huddinge, Karolinska Institute, Sweden, 3 Janssen Nordics, Solna, Stockholm, Sweden, 4 Department of Infectious Diseases, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 5 Department of Infectious Diseases, Malmö University Hospital, Malmö, Sweden, 6 Department of Infectious Diseases, Venhälsan-Södersjukhuset, Stockholm, Sweden, 7 Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden, 8 Department of Infectious Diseases, Karolinska University Hospital, Huddinge, Sweden

* veronica.svedhem-johansson@karolinska.se

Abstract

Background

As HIV infection needs a lifelong treatment, studying drug therapy duration and factors influencing treatment durability is crucial. The Swedish database InfCareHIV includes high quality data from more than 99% of all patients diagnosed with HIV infection in Sweden and provides a unique opportunity to examine outcomes in a nationwide real world cohort.

Methods

Adult patients who started a new therapy defined as a new 3rd agent (all antiretrovirals that are not N[t]RTIs) 2009–2014 with more than 100 observations in treatment-naïve or treatment-experienced patients were included. Dolutegravir was excluded due to short follow up period. Multivariate Cox proportional hazards models were used to estimate hazard ratios for treatment discontinuation.

Results

In treatment-naïve 2541 patients started 2583 episodes of treatments with a 3rd agent. Efavirenz was most commonly used (n = 1096) followed by darunavir (n = 504), atazanavir (n = 386), lopinavir (n = 292), rilpivirine (n = 156) and raltegravir (n = 149). In comparison with efavirenz, patients on rilpivirine were least likely to discontinue treatment (adjusted HR 0.33; 95% CI 0.20–0.54, p < 0.001), while patients on lopinavir were most likely to discontinue treatment (adjusted HR 2.80; 95% CI 2.30–3.40, p < 0.001). Also raltegravir was associated with early treatment discontinuation (adjusted HR 1.47; 95% CI 1.12–1.92, p = 0.005). The adjusted HR for atazanavir and darunavir were not significantly different from efavirenz. In treatment-experienced 2991 patients started 4552 episodes of treatments with a 3rd agent. Darunavir was most commonly used (n = 1285), followed by atazanavir (n = 806), efavirenz
Leval and S Valgardsson are employed by Janssen Nordics. The ten authors of this manuscript have all contributed to the study according to what is stated in the Author Contributions section. Five of the authors are HIV clinicians and affiliated with academia (AH, MG, LF, BH, VS), one was a PhD student at Karolinska Institute at the time of the data analysis and manuscript preparation (EH) and four of the authors are employees at and receive salaries from Janssen (SL, AP, AL, SV). This does not alter our adherence to PLOS ONE policies on sharing data and materials. Janssen has in no other way contributed financially to this study and did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of all authors are articulated in author contribution.

Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: S Lindbäck, A Palmborg, A Leval and S Valgardsson are employed by Janssen Nordics. V Svedhem has received research grant from Gilead Nordic Fellowship Program and Stockholm County Council and honoraria as speaker and/or scientific advisor from Gilead EMEA England and Nordic, Merk SharpDohme. M. Gisslén has received research grants from Gilead Sciences. He has received honoraria as speaker and/or scientific advisor from Abbvie, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViIV, Janssen-Cilag, and Merck. L Flamholc has received honoraria as speaker and/or scientific advisor from Abbvie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViIV, Janssen-Cilag. A Häggblom has received research grant from doctors against AIDS and Gilead Nordic and honoraria as speaker from Gilead. B Heijdeman has no conflicts of interest. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.

(n = 694), raltegravir (n = 622), rilpivirine (n = 592), lopinavir (n = 291) and etravirine (n = 262). Compared to darunavir all other drugs except for rilpivirine (HR 0.66; 95% CI 0.52–0.83, p<0.001) had higher risk for discontinuation in the multivariate adjusted analyses; atazanavir (HR 1.71; 95% CI 1.48–1.97, p<0.001), efavirenz (HR 1.86; 95% CI 1.59–2.17, p<0.001), raltegravir (HR 1.35; 95% CI 1.15–1.58, p<0.001), lopinavir (HR 3.58; 95% CI 3.02–4.25, p<0.001) and etravirine (HR 1.61; 95% CI 1.31–1.98, p<0.001). Besides the 3rd agent chosen also certain baseline characteristics of patients were independently associated with differences in treatment duration. In naive patients, presence of an AIDS-defining diagnosis and the use of other backbone than TDF/FTC or ABC/3TC increased the risk for early treatment discontinuation. In treatment-experienced patients, detectable plasma viral load at the time of switch or being highly treatment experienced increased the risk for early treatment discontinuation.

Conclusions

Treatment durability is dependent on several factors among others patient characteristics and ART guidelines. The choice of 3rd agent has a strong impact and significant differences between different drugs on treatment duration exist.

Introduction

Modern HIV treatment has transformed HIV from a fatal disease to a chronic condition. Since cure is not yet possible, combination anti-retroviral treatment (cART) must be lifelong. Despite the success of therapeutic developments in the past decades [1], there are still treatment challenges to overcome; among others transmitted drug resistance, adherence, drug to drug interactions and toxicity [2–6]. Performance and characteristics of antiretroviral (ARV) HIV drug efficacy is well described from randomized clinical trials. However, these trials include a highly selected patient population excluding individuals with anticipated non-adherence e.g. due to drug abuse or psychiatric diseases or patients with interfering concomitant diseases, thereby making the trial populations less representative than the real world patients [7].

To maximize long term treatment outcomes we need to identify the most durable treatment regimens and also investigate other factors independently associated with treatment duration. The Swedish database InfCareHIV includes high quality data from more than 99% of all patients diagnosed with HIV infection in Sweden and provides a unique opportunity to examine outcomes in a nationwide real world cohort [8].

All ARVs approved by the European Medicines Agency (EMA) are available and free of charge for HIV-infected individuals in Sweden. The Swedish HIV treatment guidelines are regularly updated, with the most recent updates being from 2009 [9], 2010 [10], 2011 [11], 2014 [12] and 2016 [13]. Start of first treatment in treatment-naïve patients has been recommended in all patients with a CD4 cell count <350/µL from 2009, for all patients with CD4 cell count 350-500/ µL from 2011 and in all patients, irrespective of CD4 cell counts, from 2014. The recommended backbone nucleoside/nucleotide reverse transcriptase inhibitor (N[t]RTI) treatment in first line has been tenofovir disoproxil fumarate /emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC), the latter as first alternative in combination with boosted protease inhibitors. Efavirenz (EFV) has been recommended as initial treatment already prior to 2009 and is also recommended in all following guidelines. Rilpivirine (RPV), launched in Sweden 2012, was included as an alternative for patients with HIV-RNA <100 000 copies/mL.
from 2014. Among protease inhibitors (PIs), boosted atazanavir (ATV) and boosted darunavir (DRV) have been recommended from 2009 while lopinavir (LPV) was excluded as a first line recommendation from 2011 and onwards. Raltegravir (RAL) and dolutegravir (DTG) were included in recommended first line treatments from 2014. No specific recommendations are made in the guidelines regarding the choice of specific drugs in treatment experienced patients, in these the choice of treatment regime is individualized taking into account different variables like reason for switch, prior treatment history, drug resistance and comorbidities.

The aim of the present study was to investigate treatment duration for 3rd agents and factors that might influence duration, in the nationwide HIV cohort in Sweden. Third agents constitute all ARVs that are not N[t]RTIs and that are added to a backbone regimen (BR) of usually two N[t]RTIs. Treatment duration is the time from starting a new 3rd agent to the discontinuation of the same 3rd agent. Treatment duration was chosen as the primary effect outcome as this is a key proxy measure, reflecting the effectiveness, tolerability and convenience of a drug. This study includes all treatment-naïve and treatment-experienced patients from the national InfCareHIV cohort who started a treatment combination with any of the most commonly used 3rd agents from the non-nucleoside reverse transcriptase inhibitor class (NNRTI), the protease inhibitor class (PI) and the integrase inhibitor class (INI) between 2009 to 2014.

Methods

Cohort

InfCareHIV has been set-up as a decision support tool in daily clinical care and is also used as a consultation tool for HIV treating physicians, for research purposes and serves also as the National Quality Registry InfCareHIV in Sweden. InfCareHIV was first implemented at Karolinska University Hospital in Stockholm and at Sahlgrenska University Hospital in Gothenburg in 2003 and as of 2009 InfCareHIV was rolled out in all 30 HIV-clinics throughout the country. Patient data, biomarkers, laboratory test results, co-infections and HIV treatments are entered into InfCareHIV, allowing for national follow-up of the care of the Swedish HIV cohort with an estimated coverage of >99% of all patients diagnosed with HIV infection. All HIV patients are actively seen 2–4 times every year and data entry into InfCareHIV is done in conjunction with each clinical visit. For this study, anonymized data was extracted from the existing national registry InfCareHIV.

Naïve or treatment-experienced adult patients who started a new therapy defined as a new 3rd agent between January 1st 2009 and December 31st 2014 were included in the study and followed until the 3rd agent discontinuation, loss to follow up/death or end of study period. Third agents constitute all ARV’s that are not N[t]RTIs and that are added to a backbone regimen of usually two N[t]RTIs.

The integrase inhibitor dolutegravir, launched in Sweden in February 2014, was not included as follow-up time was too short. Patients with HIV-2 infection or under the age 18 were excluded from the analyses.

Exposure status

Included in the treatment-naïve analysis were patients starting their first treatment regimen ever during the study period 2009–2014.

Included in the treatment-experienced analysis were patients with a prior ARV treatment and starting a new treatment including a 3rd agent during 2009–2014. Patients with a prior treatment regimen only including N[t]RTIs and then starting their first regimen including a 3rd agent during the study period were denoted first line treatment experienced patients and patients with one prior 3rd agent containing regimen starting the second 3rd agent during
the study period were denoted 2\textsuperscript{nd} line treatment experienced patients. Patients switching 3\textsuperscript{rd} agents during the study period could contribute to several observation periods.

If a 3\textsuperscript{rd} agent was added without withdrawing the previous 3\textsuperscript{rd} agent the patient was still considered on original 3\textsuperscript{rd} agent and a new follow up period was started for the add on 3\textsuperscript{rd} agent. Switch from triple therapy (N[t]RTIs + 3\textsuperscript{rd} agent) to a dual or mono therapy by reducing the N[t]RTIs was still considered the same line of therapy as long as the 3\textsuperscript{rd} agent remained the same. A switch from ritonavir-boosted ATV to non-boosted ATV was considered the same line of therapy. All drugs were dosed according to label; lopinavir and raltegravir twice daily, darunavir once daily in treatment naive patients and once or twice daily in treatment-experienced patients. Treatment interruptions of 30 days or less and then continuing with the same 3\textsuperscript{rd} agent were handled as one treatment sequence in the treatment retention analysis. Treatment interruptions of more than 30 days were considered as a treatment discontinuation.

Analysis

Descriptive statistics were used to calculate number of patients on treatment. Multivariate Cox proportional hazards models were used to estimate hazard ratios for treatment discontinuation. The most commonly prescribed 3\textsuperscript{rd} agent was used as a reference. For treatment-naïve patients, it was efavirenz and for treatment-experienced patients, it was darunavir. Variables collected in the InfCareHIV cohort and with a known or theoretical relationship to either the exposure or outcome, or both, were included in the analysis to assess for potential confounding biases: age, gender, mode of transmission, region of birth, CDC class, hepatitis status, year of treatment start, baseline CD4, baseline viral load, backbone treatment used, and for treatment experienced patients also line of therapy and years since start of first ARV treatment.

Early treatment discontinuation refers to covariates or 3\textsuperscript{rd} agents with a significantly higher risk (hazard ratio) for treatment discontinuation in the multivariate Cox regression model compared to the reference. For region of birth we used a modified UNAIDS regional classification dividing the regions in 4 geographical areas; 1. Sweden, 2. Western Europe, USA, Canada, Israel, Middle East, North Africa, 3. Africa East, South, West, Central, 4. Eastern Europe, Asia, Pacific, Caribbean, and Latin America. If a CD4 count or viral load was missing at treatment start laboratory results from the first week of therapy or from the preceding 6 months were used as baseline values.

Analyses are stratified by treatment-naïve and treatment-experienced individuals. Only treatments with more than 100 observations of initiation or change of a 3\textsuperscript{rd} agent in treatment-naïve or treatment-experienced patients were included in the analyses. Adjusted and unadjusted hazard ratios (HR) with corresponding 95% confidence intervals (CI) are shown. Treatment discontinuation rates were calculated (1-Kaplan Meier *100%) overall and per therapy for both naïve and experienced patient populations at 90 days, one year, two years and three years after start of treatment. Data were analyzed using SAS version 9.2.

Ethical considerations

The InfCareHIV registry has ethical approval for studies with retrospective analyses on de-identified patient data (Regional Ethical Review Board, University of Gothenburg Dnr 532–11).

Results

After exclusions a total of 4724 patients and 7142 observations were included in the analyses. Among treatment-naïve, 2537 patients corresponding to 2583 observations and among treatment-experienced, 2991 patients corresponding to 4552 observations were included. 46
treatment-naive patients started a regimen including two 3rd agents. The 3rd agents initiated by more than 100 treatment naive patients during the study period and thereby included in the analysis were efavirenz, rilpivirine, lopinavir, atazanavir, darunavir and raltegravir. The same antiretroviral drugs were included in the analyses of treatment-experienced patients with the addition of etravirine. The mean 3rd agent treatment observation time for treatment naive and treatment experienced patients were 28.1 and 28.2 months, respectively.

Baseline characteristics

Treatment-naive patients. In treatment-naive 2537 patients initiating cART with a 3rd agent were included in the study during the six year study period 2009–2014. They were predominately male (63%) and 81% were less than 50 years old at treatment start. Transmission route was heterosexual contact in 51%, men who have sex with men (MSM) in 31%, intravenous drug use (IVDU) in 6% and other/unknown in 8%. Data on transmission route was missing in 3% of cases. Thirty-six percent of the patients had African origin, 34% were from Sweden, 16% Asian/Eastern Europe and 14% were from Western Europe/North America. In eight percent of the observations the patient had a history of AIDS diagnosis at start of their first ART. Efavirenz was the most commonly used 3rd agent (n = 1096) followed by darunavir (n = 504), atazanavir (n = 386), lopinavir (n = 292), rilpivirine (n = 156) and raltegravir (n = 149). There were differences in the use of the different ARVs in relation to patient characteristics. This was most clearly seen with rilpivirine that was rarely used in patients with high baseline viral load or low CD4 cell counts; only 3% of the rilpivirine patients had a baseline viral load >100 000 HIV-RNA copies/mL, 3% had a CD4 cell count <200/μL and none of the patients receiving rilpivirine as treatment-naïve had a history of AIDS diagnosis at treatment start. A higher proportion of the patients starting darunavir or lopinavir had a CD4 cell count below 200/μL, and together with raltegravir a higher proportion also had an AIDS diagnosis at start of treatment. Patients starting darunavir or raltegravir more often had a viral load >100 000 copies/mL. Lopinavir and atazanavir were significantly more often used in women. A full description of baseline characteristics for treatment-naive patients can be found in Table 1.

Treatment-experienced patients. During the 6 year observation period 2991 treatment-experienced patients started 4552 episodes of treatments with a 3rd agent. At treatment start 58% were male. Transmission route and country of origin were similar to treatment-naive patients. 18% had a history of AIDS at start of treatment and 13% had a CD4 cell count below 200/μL. 57% of the treatments started in a patient with a viral load <50 HIV-RNA copies/mL. In 37% of the observations the patients started a 2nd line treatment, in 23% a 3rd line and in 39% the patient started treatment line 4 or higher. Darunavir was the mostly used ART with 1285 observed treatments followed by 806 observed treatments with atazanavir. A full description of baseline characteristics for treatment-experienced patient can be found in Table 2.

Overall treatment discontinuation rates. Ten percent of treatment naive patients had discontinued the 3rd agent within 90 days from start of treatment. After one year 24% had discontinued, after two years 33% and after three years 42%. Among treatment-experienced patients overall discontinuation rates were very similar; 11% after 90 days, 24% after one year, 34% after two years and 41% after three years. Discontinuation rates varied widely between drugs with the highest discontinuation rates seen with lopinavir; approximately half of the patients, both in treatment-naïve and treatment-experienced patients had discontinued lopinavir within one year from treatment start. The lowest discontinuation rate was seen in patients treated with rilpivirine where only 7% and 12% of treatment-naive and treatment-experienced patients respectively discontinued within one year. Discontinuation rates for all drugs can be found in Table 3.
Table 1. Baseline characteristics for treatment-naive patients.

| Covariate                          | Value                        | Efavirenz (n = 1096) | Rilpivirine (n = 156) | Lopinavir (n = 292) | Atazanavir (n = 386) | Darunavir (n = 504) | Raltegravir (n = 149) | Total (n = 2583) |
|-----------------------------------|-----------------------------|----------------------|----------------------|--------------------|----------------------|---------------------|----------------------|------------------|
| **Age**                           |                             |                      |                      |                    |                      |                     |                      |                  |
| Age <50                           |                             | 878 (80.1%)          | 133 (85.3%)          | 258 (88.4%)        | 317 (82.1%)          | 401 (79.6%)         | 114 (76.5%)         | 2101 (81.3%)     |
| Age ≥50                           |                             | 218 (19.9%)          | 23 (14.7%)           | 34 (11.6%)         | 69 (17.9%)           | 102 (20.2%)         | 35 (23.5%)          | 481 (18.6%)      |
| Missing                           |                             | 1 (0.2%)             | 1 (0.6%)             | 3 (1.0%)           | 3 (0.8%)             | 36 (7.1%)           | 27 (18.1%)          | 74 (2.9%)        |
| **NRTI Backbone**                 |                             |                      |                      |                    |                      |                     |                      |                  |
| No Backbone                       |                             | 4 (0.4%)             | 1 (0.6%)             | 3 (1.0%)           | 3 (0.8%)             | 36 (7.1%)           | 27 (18.1%)          | 74 (2.9%)        |
| ABC/3TC                           | 183 (16.7%)                 | 4 (2.6%)             | 69 (23.6%)           | 162 (42.0%)        | 166 (32.9%)          | 14 (9.4%)           | 598 (23.2%)        |
| TDF/FTC                           | 863 (78.7%)                 | 151 (96.8%)          | 102 (34.9%)          | 205 (53.1%)        | 298 (59.1%)          | 102 (68.5%)         | 1721 (66.6%)       |
| **Other**                         |                             |                      |                      |                    |                      |                     |                      |                  |
| **CD4 cell count at baseline**    |                             |                      |                      |                    |                      |                     |                      |                  |
| ≤200                              |                             | 316 (28.8%)          | 5 (3.2%)             | 104 (35.6%)        | 110 (28.5%)          | 175 (34.7%)         | 43 (28.9%)          | 753 (29.2%)      |
| 201–350                           |                             | 394 (35.9%)          | 39 (25.0%)           | 90 (30.8%)         | 152 (39.4%)          | 146 (29.0%)         | 28 (18.8%)          | 849 (32.9%)      |
| 351–500                           |                             | 207 (18.9%)          | 58 (37.2%)           | 47 (16.1%)         | 70 (18.1%)           | 106 (21.0%)         | 45 (30.2%)          | 533 (20.6%)      |
| >500                              |                             | 88 (8.0%)            | 47 (30.1%)           | 31 (10.6%)         | 37 (9.6%)            | 50 (9.9%)           | 24 (16.1%)          | 277 (10.7%)      |
| Missing                           |                             | 91 (8.3%)            | 7 (4.5%)             | 20 (6.8%)          | 17 (4.4%)            | 27 (5.4%)           | 9 (6.0%)            | 171 (6.6%)       |
| **CDC Class**                     |                             |                      |                      |                    |                      |                     |                      |                  |
| C/AIDS                            | 75 (6.8%)                   | 42 (14.4%)           | 27 (7.0%)            | 53 (10.5%)         | 21 (14.1%)           | 218 (8.4%)          |                      |                  |
| Non-C (i.e. A or B)              | 1021 (93.2%)                | 156 (100.0%)         | 250 (85.6%)          | 359 (93.0%)        | 451 (89.5%)          | 128 (85.9%)         | 2365 (91.6%)       |
| **Region of birth**               |                             |                      |                      |                    |                      |                     |                      |                  |
| Sweden                            | 357 (32.6%)                 | 62 (39.7%)           | 57 (19.5%)           | 125 (32.4%)        | 201 (39.9%)          | 64 (43.0%)          | 866 (33.5%)         |
| Western Europe, USA, Israel, Canada, North Africa, Middle East | 152 (13.9%) | 38 (24.4%) | 18 (6.2%) | 46 (11.9%) | 71 (14.1%) | 33 (22.1%) | 358 (13.9%) |
| Africa (East, South, West and Central) | 405 (37.0%) | 28 (17.9%) | 157 (53.8%) | 147 (38.1%) | 147 (29.2%) | 36 (24.2%) | 920 (35.6%) |
| Eastern Europe, Asia, Pacific, Caribbean, Latin America | 168 (15.3%) | 25 (16.0%) | 57 (19.5%) | 63 (16.3%) | 74 (14.7%) | 15 (10.1%) | 402 (15.6%) |
| Missing                           | 14 (1.3%)                   | 3 (1.9%)             | 3 (1.0%)             | 5 (1.3%)           | 11 (2.2%)            | 1 (0.7%)            | 37 (1.4%)           |
| **Gender**                        |                             |                      |                      |                    |                      |                     |                      |                  |
| Male                              | 779 (71.1%)                 | 120 (76.9%)          | 90 (30.8%)           | 202 (52.3%)        | 334 (66.3%)          | 105 (70.5%)         | 1630 (63.1%)        |
| Female                            | 317 (28.9%)                 | 36 (23.1%)           | 202 (69.2%)          | 184 (47.7%)        | 170 (33.7%)          | 44 (29.5%)          | 953 (36.9%)         |
| **Hepatitis status**              |                             |                      |                      |                    |                      |                     |                      |                  |
| Negative                          | 1066 (97.3%)                | 151 (96.8%)          | 280 (95.9%)          | 360 (93.3%)        | 477 (94.6%)          | 145 (97.3%)         | 2479 (96.0%)        |
| Hep B seropositive                | 14 (1.3%)                   | 2 (1.3%)             | 3 (1.0%)             | 4 (1.0%)           | 6 (1.2%)             | 1 (0.7%)            | 30 (1.2%)           |
| Hep C seropositive                | 16 (1.5%)                   | 3 (1.9%)             | 8 (2.7%)             | 22 (5.7%)          | 19 (3.8%)            | 3 (2.0%)            | 71 (2.7%)           |
| Hep B+C seropositive              | 1 (0.3%)                    | 1 (0.3%)             | 2 (0.4%)             | 2 (0.4%)           |                     |                     | 3 (0.1%)            |
| **Transmission Route**            |                             |                      |                      |                    |                      |                     |                      |                  |
| Heterosexual                      | 572 (52.2%)                 | 52 (33.3%)           | 193 (66.1%)          | 219 (56.7%)        | 229 (45.4%)          | 52 (34.9%)          | 1317 (51.0%)        |
| MSM                               | 353 (32.2%)                 | 90 (57.7%)           | 27 (9.2%)            | 83 (21.5%)         | 176 (34.9%)          | 81 (54.4%)          | 810 (31.4%)         |
| IVDU                              | 39 (3.6%)                   | 5 (3.2%)             | 23 (7.9%)            | 35 (9.1%)          | 44 (8.7%)            | 5 (3.4%)            | 151 (5.8%)          |
| Other/unknown                     | 100 (9.1%)                  | 4 (2.6%)             | 42 (14.4%)           | 38 (9.8%)          | 26 (5.2%)            | 9 (6.0%)            | 219 (8.5%)          |
| Missing                           | 32 (2.9%)                   | 5 (3.2%)             | 7 (2.4%)             | 11 (2.8%)          | 29 (5.8%)            | 2 (1.3%)            | 86 (3.3%)           |

(Continued)
Analysis of treatment duration

**Treatment-naïve patients.** Among treatment-naïve patients the 3rd agents had different discontinuation rates. In comparison with efavirenz, patients on rilpivirine were least likely to discontinue treatment (adjusted HR 0.33; 95% CI 0.20–0.54, p < 0.001), while patients on lopinavir were most likely to discontinue treatment (adjusted HR 2.80; 95% CI 2.30–3.40, p < 0.001), see Fig 1A. Also raltegravir was associated with early treatment discontinuation (adjusted HR 1.47; 95% CI 1.12–1.92, p = 0.005). The adjusted HR for atazanavir and darunavir were not significantly different from efavirenz. Hazard ratios for treatment-naive patients can be seen in Fig 1.

Patients with an AIDS diagnosis at treatment start had a significantly higher risk for early treatment discontinuation than non-AIDS patients. Other co-variables independently associated with early treatment discontinuation in the multivariate adjusted model were N[t]RTI backbone other than ABC/3TC or TAF/FTC and treatment start year 2011 or later compared to treatment start 2009–2010.

When transmission route was known to be heterosexual, patients were less likely to discontinue 3rd agent treatment than MSM (adjusted HR 0.66; 95% CI 0.52–0.83, p < 0.001) and all other drugs had significantly higher risk for discontinuation in the multivariate adjusted analyses; efavirenz (HR 1.86; 95% CI 1.59–2.17, p < 0.001), etravirine (HR 1.61; 95% CI 1.31–1.98, p < 0.001), lopinavir (HR 3.58; 95% CI 3.02–4.25, p < 0.001), atazanavir (HR 1.71; 95% CI 1.48–1.97, p < 0.001), and raltegravir (HR 1.35; 95% CI 1.15–1.58, p < 0.001) (see Fig 2).

**Table 1.** (Continued)

| Covariate                      | Value         | Efavirenz (n = 1096) | Rilpivirine (n = 156) | Lopinavir (n = 292) | Atazanavir (n = 386) | Darunavir (n = 504) | Raltegravir (n = 149) | Total (n = 2583) |
|-------------------------------|---------------|----------------------|-----------------------|---------------------|----------------------|---------------------|----------------------|-----------------|
| Treatment Start Year          |               |                      |                       |                     |                      |                     |                      |                 |
| 2009–2010                     | 449 (41.0%)   | 4 (2.6%)             | 202 (69.2%)           | 197 (51.0%)         | 53 (10.5%)           | 28 (18.8%)          | 933 (36.1%)         |                 |
| 2011–2012                     | 384 (35.0%)   | 38 (24.4%)           | 72 (24.7%)            | 116 (30.1%)         | 228 (45.2%)          | 52 (34.9%)          | 890 (34.5%)         |                 |
| 2013–2014                     | 263 (24.0%)   | 114 (73.1%)          | 18 (6.2%)             | 73 (18.9%)          | 223 (44.2%)          | 69 (46.3%)          | 760 (29.4%)         |                 |
| Baseline Viral Load           |               |                      |                       |                     |                      |                     |                      |                 |
| <50                           | 19 (1.7%)     | 4 (2.6%)             | 13 (4.5%)             | 7 (1.8%)            | 9 (1.8%)             | 5 (3.4%)            | 57 (2.2%)           |                 |
| 51–1,000                      | 48 (4.4%)     | 14 (9.0%)            | 21 (7.2%)             | 18 (4.7%)           | 22 (4.4%)            | 7 (4.7%)            | 130 (5.0%)          |                 |
| 1,001–10,000                  | 143 (13.0%)   | 62 (39.7%)           | 54 (18.5%)            | 62 (16.1%)          | 70 (13.9%)           | 16 (10.7%)          | 407 (15.8%)         |                 |
| 10,001–100,000                | 407 (37.1%)   | 65 (41.7%)           | 105 (36.0%)           | 150 (38.9%)         | 191 (37.9%)          | 60 (40.3%)          | 978 (37.9%)         |                 |
| >100,000                      | 359 (32.8%)   | 4 (2.6%)             | 73 (25.0%)            | 120 (31.1%)         | 186 (36.9%)          | 51 (34.2%)          | 793 (30.7%)         |                 |
| Missing                       | 120 (10.9%)   | 7 (4.5%)             | 26 (8.9%)             | 29 (7.5%)           | 26 (5.2%)            | 10 (6.7%)           | 218 (8.4%)          |                 |
| Age (median, p25-p75)         |               | 39 (32–47)           | 37 (31–46)            | 35 (29–41)          | 37 (31–45)           | 39 (32–48)          | 40 (33–48)          | 38 (31–47)       |
| Year Start 1st Line Treatment (median, p25-p75) | 2011 (2010–2012) | 2013 (2012–2013) | 2010 (2009–2011) | 2010 (2010–2012) | 2012 (2011–2013) | 2012 (2011–2014) | 2011 (2010–2013) |

doi:10.1371/journal.pone.0171227.t001
Table 2. Baseline characteristics for treatment-experienced patients.

| Covariate               | Value                          | Efavirenz (n = 694) | Etravirine (n = 262) | Rilpivirine (n = 592) | Lopinavir (n = 291) | Atazanavir (n = 806) | Darunavir (n = 1285) | Raltegravir (n = 622) | Total (n = 4552) |
|-------------------------|--------------------------------|---------------------|----------------------|----------------------|---------------------|---------------------|----------------------|----------------------|------------------|
| Age                     | Age <50                        | 536 (77.2%)         | 164 (62.6%)          | 404 (66.2%)          | 212 (72.9%)         | 602 (74.7%)         | 868 (67.5%)         | 358 (57.6%)         | 3144 (68.1%)     |
|                         | Age ≥50                        | 158 (22.8%)         | 98 (37.4%)           | 188 (31.8%)          | 77 (26.5%)          | 204 (25.3%)         | 416 (32.4%)         | 262 (42.1%)         | 1403 (30.8%)     |
| Missing                 |                                | 2 (0.7%)            | 1 (0.1%)             | 1 (0.3%)             | 2 (0.2%)            | 2 (0.3%)            | 5 (0.1%)            |                      | 5 (0.1%)         |
| NRTI Backbone           | No Backbone                    | 4 (0.6%)            | 77 (29.4%)           | 8 (1.4%)             | 18 (6.2%)           | 8 (1.0%)            | 137 (10.7%)         | 104 (16.7%)         | 356 (7.8%)       |
|                         | ABC/3TC                        | 128 (18.4%)         | 38 (14.5%)           | 115 (19.4%)          | 95 (32.6%)          | 379 (47.0%)         | 447 (34.8%)         | 174 (28.0%)         | 1376 (30.2%)     |
|                         | TDF/FTC                        | 530 (76.4%)         | 106 (40.5%)          | 461 (77.9%)          | 107 (36.8%)         | 385 (47.8%)         | 601 (46.8%)         | 273 (43.9%)         | 2463 (54.1%)     |
|                         | Other                          | 41 (15.6%)          | 8 (1.4%)             | 71 (24.4%)           | 34 (4.2%)           | 100 (7.8%)          | 71 (11.4%)          |                      | 357 (7.8%)       |
| CD4 cell count at baseline | ≤200                           | 73 (10.5%)          | 34 (13.0%)           | 25 (4.2%)            | 54 (18.6%)          | 107 (13.3%)         | 220 (17.1%)         | 93 (15.0%)          | 606 (13.3%)      |
|                         | 201–350                        | 153 (22.0%)         | 48 (18.3%)           | 70 (11.8%)           | 87 (29.9%)          | 216 (26.8%)         | 268 (20.9%)         | 102 (16.4%)         | 944 (20.7%)      |
|                         | 351–500                        | 165 (23.8%)         | 61 (23.3%)           | 123 (20.8%)          | 56 (19.2%)          | 188 (23.3%)         | 283 (22.0%)         | 116 (18.6%)         | 992 (21.8%)      |
|                         | >500                            | 247 (35.6%)         | 94 (35.9%)           | 290 (49.0%)          | 68 (23.4%)          | 236 (29.3%)         | 421 (32.8%)         | 250 (40.2%)         | 1606 (35.3%)     |
| Missing                 |                                | 56 (8.1%)           | 25 (9.5%)            | 84 (14.2%)           | 26 (8.9%)           | 59 (7.3%)           | 93 (7.2%)           | 61 (9.8%)           | 404 (8.9%)       |
| CDC Class               | C/AIDS                         | 105 (15.1%)         | 71 (27.1%)           | 79 (13.3%)           | 60 (20.6%)          | 124 (15.4%)         | 238 (18.5%)         | 146 (23.5%)         | 823 (18.1%)      |
|                         | Non-C (i.e. A or B)            | 589 (84.9%)         | 191 (72.9%)          | 513 (86.7%)          | 231 (79.4%)         | 682 (84.6%)         | 1047 (81.5%)        | 476 (76.5%)         | 3729 (81.9%)     |
| Region of birth         | Sweden                         | 222 (32.0%)         | 140 (53.4%)          | 260 (43.9%)          | 102 (35.1%)         | 293 (36.4%)         | 496 (38.6%)         | 303 (48.7%)         | 1816 (39.9%)     |
|                         | Western Europe, USA, Israel, Canada, North Africa, Middle East | 78 (11.2%) | 43 (16.4%) | 104 (17.6%) | 20 (6.9%) | 80 (9.9%) | 161 (12.5%) | 90 (14.5%) | 576 (12.7%) |
|                         | Africa (East, South, West and Central) | 264 (40.9%) | 58 (22.1%) | 151 (25.5%) | 126 (43.3%) | 323 (40.1%) | 485 (37.7%) | 171 (27.5%) | 1598 (35.1%) |
|                         | Eastern Europe, Asia, Pacific, Caribbean, Latin America | 102 (14.7%) | 21 (8.0%) | 66 (11.1%) | 11 (1.9%) | 10 (0.8%) | 6 (1.0%) | 41 (0.9%) |
| Missing                 |                                | 8 (1.2%)            | 11 (1.9%)            | 2 (0.7%)             | 4 (0.5%)            | 10 (0.8%)           | 6 (1.0%)            |                      | 41 (0.9%)        |
| Gender                  | Male                           | 365 (52.6%)         | 195 (74.4%)          | 398 (67.2%)          | 129 (44.3%)         | 404 (50.1%)         | 753 (58.6%)         | 407 (65.4%)         | 2651 (58.2%)     |
|                         | Female                         | 329 (47.4%)         | 67 (25.6%)           | 194 (32.8%)          | 162 (55.7%)         | 402 (49.9%)         | 532 (41.4%)         | 215 (34.6%)         | 1901 (41.8%)     |
| Hepatitis status        | Negative                       | 651 (93.8%)         | 251 (95.8%)          | 554 (93.6%)          | 271 (93.1%)         | 733 (90.9%)         | 1197 (93.2%)        | 584 (93.9%)         | 4241 (93.2%)     |
|                         | Hep B seropositive             | 18 (2.6%)           | 5 (1.9%)             | 13 (2.2%)            | 1 (0.3%)            | 10 (1.2%)           | 27 (2.1%)           | 12 (1.9%)           | 86 (1.9%)        |
|                         | Hep C seropositive             | 23 (3.3%)           | 6 (2.3%)             | 23 (3.9%)            | 18 (6.2%)           | 61 (7.6%)           | 56 (4.4%)           | 26 (4.2%)           | 213 (4.7%)       |
|                         | Hep B+C seropositive           | 2 (0.3%)            | 2 (0.3%)             | 1 (0.3%)             | 2 (0.2%)            | 5 (0.4%)            |                      |                      | 12 (0.3%)        |
| Transmission Route      | Heterosexual                   | 416 (59.9%)         | 96 (36.6%)           | 263 (44.4%)          | 181 (62.2%)         | 464 (57.6%)         | 669 (52.1%)         | 268 (43.1%)         | 2357 (51.8%)     |
|                         | MSM                            | 186 (26.8%)         | 142 (54.2%)          | 272 (45.9%)          | 44 (15.1%)          | 168 (20.8%)         | 366 (28.5%)         | 276 (44.4%)         | 1454 (31.9%)     |

(Continued)
Having a CD4 cell count <200 μL or a viral load >50 HIV-RNA copies/mL at treatment start significantly increased the risk for early treatment discontinuation in the adjusted analyses. Female gender, treatment line 4+ or treatment start 2011 or later also increased the risk. Similar to findings in treatment naive patients, heterosexual transmission route correlated to a lower risk and having a backbone other than ABC/3TC or TDF/FTC correlated to a higher risk for early discontinuation of the 3rd agent. Treatment experienced patients with no backbone had a lower risk for early treatment discontinuation as well as patients with Asian origin. For complete results, see Table 5.

Table 2. (Continued)

| Covariate Value | Efavirenz (n = 694) | Etravirine (n = 262) | Rilpivirine (n = 592) | Lopinavir (n = 291) | Atazanavir (n = 806) | Darunavir (n = 1285) | Raltegravir (n = 622) | Total (n = 4552) |
|------------------|---------------------|----------------------|----------------------|---------------------|---------------------|---------------------|---------------------|------------------|
| IVDU             | 28 (4.0%)           | 10 (3.8%)            | 17 (2.9%)            | 38 (13.1%)          | 106 (13.2%)         | 129 (10.0%)         | 30 (4.8%)          | 358 (7.9%)       |
| Other/unknown    | 60 (8.6%)           | 13 (5.0%)            | 36 (6.1%)            | 23 (7.9%)           | 62 (7.7%)           | 114 (8.9%)          | 45 (7.2%)          | 353 (7.8%)       |
| Missing          | 4 (0.6%)            | 1 (0.4%)             | 4 (0.7%)             | 5 (1.7%)            | 6 (0.7%)            | 7 (0.5%)            | 3 (0.5%)           | 30 (0.7%)        |
| Treatment Start Year                                      |                     |                      |                      |                     |                     |                     |                    |                  |
| 2009–2010        | 377 (54.3%)         | 121 (46.2%)          | 194 (66.7%)          | 424 (52.6%)         | 327 (25.4%)         | 211 (33.9%)         | 1654 (36.3%)       |                  |
| 2011–2012        | 218 (31.4%)         | 80 (30.5%)           | 74 (25.4%)           | 266 (33.0%)         | 545 (42.4%)         | 232 (37.3%)         | 1617 (35.5%)       |                  |
| 2013–2014        | 99 (14.3%)          | 61 (23.3%)           | 23 (7.9%)            | 116 (14.4%)         | 413 (32.1%)         | 179 (28.8%)         | 1281 (28.1%)       |                  |
| Line of Therapy  | 1*                  | 30 (4.3%)            | 5 (0.8%)             | 5 (1.7%)            | 13 (1.6%)           | 8 (0.6%)            | 4 (0.6%)           | 66 (1.4%)        |
| 2                | 352 (50.7%)         | 31 (11.8%)           | 119 (40.9%)          | 336 (41.7%)         | 391 (30.4%)         | 157 (25.2%)         | 1647 (36.2%)       |                  |
| 3                | 164 (23.6%)         | 43 (16.4%)           | 130 (22.0%)          | 75 (25.8%)          | 204 (25.3%)         | 311 (24.2%)         | 130 (20.9%)        | 1057 (23.2%)     |
| 4+               | 148 (21.3%)         | 187 (71.4%)          | 196 (33.1%)          | 92 (31.6%)          | 253 (31.4%)         | 575 (44.7%)         | 331 (53.2%)        | 1782 (39.1%)     |
| Baseline Viral Load                                      |                     |                      |                      |                     |                     |                     |                    |                  |
| <50              | 433 (62.4%)         | 136 (51.9%)          | 515 (87.0%)          | 98 (33.7%)          | 424 (52.6%)         | 649 (50.5%)         | 358 (57.6%)        | 2613 (57.4%)     |
| 51–1,000         | 65 (9.4%)           | 59 (22.5%)           | 31 (5.2%)            | 49 (16.8%)          | 98 (12.2%)          | 236 (18.4%)         | 120 (19.3%)        | 658 (14.5%)      |
| 1,001–10,000     | 55 (7.9%)           | 18 (6.9%)            | 18 (3.0%)            | 36 (12.4%)          | 68 (8.4%)           | 102 (7.9%)          | 41 (6.6%)          | 338 (7.4%)       |
| 10,001–100,000   | 76 (11.0%)          | 29 (11.1%)           | 13 (2.2%)            | 53 (18.2%)          | 116 (14.4%)         | 165 (12.8%)         | 60 (9.6%)          | 512 (11.2%)      |
| >100,000         | 34 (4.9%)           | 16 (6.1%)            | 3 (0.5%)             | 37 (12.7%)          | 65 (8.1%)           | 110 (8.6%)          | 26 (4.2%)          | 291 (6.4%)       |
| Missing          | 31 (4.5%)           | 4 (1.5%)             | 12 (2.0%)            | 18 (6.2%)           | 35 (4.3%)           | 23 (1.8%)           | 17 (2.7%)          | 140 (3.1%)       |
| Years Since Start of first ART                            |                     |                      |                      |                     |                     |                     |                    |                  |
| 0–2 years        | 278 (40.1%)         | 56 (21.4%)           | 190 (32.1%)          | 108 (37.1%)         | 289 (35.9%)         | 327 (25.4%)         | 165 (26.5%)        | 1413 (31.0%)     |
| 3–5 years        | 106 (15.3%)         | 23 (8.8%)            | 101 (17.1%)          | 48 (16.5%)          | 122 (15.1%)         | 170 (13.2%)         | 53 (8.5%)          | 623 (13.7%)      |
| 5+ years         | 310 (44.7%)         | 183 (69.8%)          | 301 (50.8%)          | 135 (46.4%)         | 395 (49.0%)         | 788 (61.3%)         | 404 (65.0%)        | 2516 (55.3%)     |
| Age (median, p25-p75)                                      |                     |                      |                      |                     |                     |                     |                    |                  |
| 41 (34–49)       | 47 (41–56)          | 44 (37–53)           | 41 (34–50)           | 42 (35–50)          | 44 (37–52)          | 47 (40–56)          | 44 (36–52)         |                  |
| Year Start of first ART (median, p25-p75)                  |                     |                      |                      |                     |                     |                     |                    |                  |
| 2006 (2001–2009) | 2000 (1997–2007)    | 2008 (2002–2011)     | 2006 (2001–2008)     | 2006 (2002–2009)    | 2005 (1998–2009)    | 2003 (1998–2009)    | 2005 (1999–2009)   |                  |

*Includes patients with a prior treatment episode including only N[t]RTIs and starting their first treatment including a 3rd agent during the study period 2009–2014

doi:10.1371/journal.pone.0171227.t002
As HIV infection needs lifelong treatment, studying treatment duration and factors influencing treatment durability is crucial. This can be done in randomized clinical trials but, for several reasons, a real life cohort study like ours can give additional benefits.

First, in a randomized clinical trial you study a selected, small, homogeneous patient group in a strictly standardized setting in order to be able to attribute the effect to the specific intervention, for example, the efficacy of a drug. This might lead to results less applicable outside

### Table 3. Discontinuation rates (1-KM*100%) for treatment-naive and treatment-experienced patient populations.

| Patient Population | Treatment | 90 days   | 1 year    | 2 years   | 3 years   |
|--------------------|-----------|-----------|-----------|-----------|-----------|
| Naive              | Efavirenz | 0.10 (0.09;0.12) | 0.21 (0.19;0.24) | 0.29 (0.26;0.32) | 0.35 (0.32;0.38) |
|                    | Rilpivirine | 0.04 (0.02;0.08) | 0.07 (0.04;0.13) | 0.11 (0.07;0.18) | 0.17 (0.10;0.28) |
|                    | Lopinavir | 0.16 (0.13;0.21) | 0.52 (0.46;0.58) | 0.69 (0.64;0.74) | 0.79 (0.74;0.83) |
|                    | Atazanavir | 0.10 (0.07;0.14) | 0.22 (0.18;0.26) | 0.29 (0.25;0.34) | 0.36 (0.31;0.41) |
|                    | Darunavir | 0.07 (0.05;0.09) | 0.18 (0.15;0.22) | 0.28 (0.24;0.33) | 0.41 (0.36;0.47) |
|                    | Raltegravir | 0.13 (0.09;0.20) | 0.33 (0.26;0.42) | 0.43 (0.35;0.53) | 0.59 (0.50;0.69) |
|                    | Total | 0.10 (0.09;0.11) | 0.24 (0.22;0.26) | 0.33 (0.32;0.35) | 0.42 (0.40;0.44) |
| Experienced        | Efavirenz | 0.16 (0.13;0.19) | 0.30 (0.27;0.34) | 0.38 (0.35;0.42) | 0.44 (0.40;0.48) |
|                    | Etravirine | 0.17 (0.13;0.22) | 0.29 (0.24;0.35) | 0.41 (0.35;0.47) | 0.47 (0.40;0.53) |
|                    | Rilpivirine | 0.06 (0.04;0.08) | 0.12 (0.09;0.15) | 0.16 (0.13;0.20) | 0.22 (0.18;0.28) |
|                    | Lopinavir | 0.20 (0.16;0.25) | 0.50 (0.44;0.56) | 0.68 (0.63;0.74) | 0.76 (0.71;0.81) |
|                    | Atazanavir | 0.10 (0.08;0.12) | 0.25 (0.22;0.28) | 0.38 (0.34;0.41) | 0.45 (0.42;0.49) |
|                    | Darunavir | 0.07 (0.06;0.09) | 0.18 (0.16;0.20) | 0.28 (0.25;0.30) | 0.33 (0.30;0.36) |
|                    | Raltegravir | 0.11 (0.08;0.13) | 0.26 (0.23;0.30) | 0.34 (0.30;0.38) | 0.41 (0.37;0.46) |
|                    | Total | 0.11 (0.10;0.12) | 0.24 (0.23;0.25) | 0.34 (0.33;0.36) | 0.41 (0.39;0.42) |

doi:10.1371/journal.pone.0171227.t003

**Discussion**

As HIV infection needs lifelong treatment, studying treatment duration and factors influencing treatment durability is crucial. This can be done in randomized clinical trials but, for several reasons, a real life cohort study like ours can give additional benefits.

First, in a randomized clinical trial you study a selected, small, homogeneous patient group in a strictly standardized setting in order to be able to attribute the effect to the specific intervention, for example, the efficacy of a drug. This might lead to results less applicable outside

![Fig 1. Risk for treatment discontinuation in treatment-naive patients (Treatment effects showing Hazard Ratios from univariate and multivariate Cox regression models).](https://doi.org/10.1371/journal.pone.0171227.g001)
Table 4. Hazard Ratios from univariate and multivariate Cox regression models for treatment-naive patients.

| Covariate                              | Value          | Distinct Patients (n) | Observations (n) | HR (95% CI) univariate model | P-value | HR (95% CI) multivariate model* | P-value |
|----------------------------------------|----------------|-----------------------|------------------|-----------------------------|---------|-------------------------------|---------|
| Age                                    | Age <50        | 2068                  | 2101             | Reference                    |         | Reference                      |         |
|                                        | Age ≥50        | 472                   | 481              | 0.88 (0.75;1.03)             | 0.111   | 0.95 (0.80;1.12)              | 0.548   |
|                                        | Missing        | 1                     | 1                | 10.58 (1.50;74.82)           | 0.018   | 23.78 (3.21;175.91)           | 0.002   |
| N[t]RTI Backbone                      | No Backbone    | 50                    | 74               | 1.57 (1.16;2.13)             | 0.004   | 1.24 (0.89;1.73)              | 0.210   |
|                                        | ABC/3TC        | 597                   | 598              | 1.16 (1.00;1.35)             | 0.045   | 1.06 (0.91;1.25)              | 0.439   |
|                                        | TDF/FTC        | 1708                  | 1721             | Reference                    |         | Reference                      |         |
|                                        | Other          | 186                   | 190              | 3.01 (2.51;3.61)             | <0.001  | 2.16 (1.72;2.71)              | <0.001  |
| CD4 cell count at Baseline             | ≤200           | 736                   | 753              | 0.90 (0.73;1.12)             | 0.358   | 0.83 (0.65;1.05)              | 0.127   |
|                                        | 201–350        | 840                   | 849              | 0.73 (0.59;0.90)             | 0.004   | 0.77 (0.62;0.97)              | 0.025   |
|                                        | 351–500        | 524                   | 533              | 0.86 (0.68;1.08)             | 0.187   | 0.87 (0.69;1.10)              | 0.260   |
|                                        | >500           | 272                   | 277              | Reference                    |         | Reference                      |         |
|                                        | Missing        | 169                   | 171              | 0.66 (0.49;0.90)             | 0.008   | 0.60 (0.39;0.94)              | 0.024   |
| CDC Class                              | C/AIDS         | 207                   | 218              | 1.56 (1.29;1.88)             | <0.001  | 1.42 (1.15;1.76)              | 0.001   |
|                                        | Non-C (i.e. A or B) | 2334              | 2365             | Reference                    |         | Reference                      |         |
| Region of birth                        | Sweden         | 849                   | 866              | Reference                    |         | Reference                      |         |
|                                        | Western Europe, USA, Israel, Canada, North Africa, Middle East | 353 | 358 | 0.98 (0.81;1.19) | 0.861 | 1.00 (0.82;1.21) | 0.970 |
|                                        | Africa (East, South, West and Central) | 901 | 920 | 1.06 (0.92;1.22) | 0.436 | 1.08 (0.90;1.30) | 0.409 |
|                                        | Eastern Europe, Asia, Pacific, Caribbean, Latin America | 401 | 402 | 0.91 (0.75;1.10) | 0.316 | 0.85 (0.69;1.05) | 0.141 |
|                                        | Missing        | 37                    | 37               | 0.65 (0.35;1.22)             | 0.182   | 0.83 (0.43;1.62)              | 0.587   |
| Gender                                 | Male           | 1608                  | 1630             | Reference                    |         | Reference                      |         |
|                                        | Female         | 933                   | 953              | 1.13 (1.00;1.27)             | 0.060   | 1.02 (0.86;1.21)              | 0.809   |
| Hepatitis Status                       | Negative       | 2438                  | 2479             | Reference                    |         | Reference                      |         |
|                                        | Hep B seropositive | 30                | 30               | 0.84 (0.46;1.52)             | 0.565   | 0.88 (0.49;1.61)              | 0.688   |
|                                        | Hep C seropositive | 70               | 71               | 1.16 (0.83;1.61)             | 0.381   | 1.21 (0.84;1.73)              | 0.314   |
|                                        | Hep B+C seropositive | 3               | 3                | 2.07 (0.52;8.27)             | 0.305   | 1.75 (0.43;7.17)              | 0.434   |
| Transmission Route                     | Heterosexual   | 1293                  | 1317             | 0.86 (0.75;0.99)             | 0.029   | 0.67 (0.56;0.80)              | <0.001  |
|                                        | MSM            | 796                   | 810              | Reference                    |         | Reference                      |         |
|                                        | IVDU           | 151                   | 151              | 0.95 (0.73;1.23)             | 0.703   | 0.78 (0.58;1.04)              | 0.094   |
|                                        | Other/unknown  | 215                   | 219              | 1.15 (0.92;1.43)             | 0.211   | 0.82 (0.64;1.06)              | 0.139   |
|                                        | Missing        | 86                    | 86               | 0.61 (0.39;0.93)             | 0.023   | 0.56 (0.35;0.89)              | 0.015   |
| Treatment Start Year                   | 2009–2010      | 926                   | 933              | Reference                    |         | Reference                      |         |
|                                        | 2011–2012      | 865                   | 890              | 0.98 (0.85;1.12)             | 0.765   | 1.16 (1.00;1.35)              | 0.048   |
|                                        | 2013–2014      | 750                   | 760              | 0.84 (0.70;1.00)             | 0.049   | 1.26 (1.03;1.54)              | 0.023   |
| Baseline Viral Load                    | <50            | 54                    | 57               | Reference                    |         | Reference                      |         |
|                                        | 51–1,000       | 128                   | 130              | 0.83 (0.50;1.37)             | 0.458   | 1.09 (0.65;1.81)              | 0.749   |
|                                        | 1,001–10,000   | 405                   | 407              | 0.86 (0.55;1.34)             | 0.493   | 1.15 (0.73;1.82)              | 0.536   |
|                                        | 10,001–100,000 | 957                | 978              | 0.83 (0.54;1.28)             | 0.399   | 1.11 (0.72;1.73)              | 0.639   |
|                                        | >100,000       | 781                   | 793              | 1.00 (0.65;1.53)             | 0.986   | 1.33 (0.85;2.08)              | 0.214   |
| 3rd Agent                              | Efavirenz      | 1096                  | 1096             | Reference                    |         | Reference                      |         |
|                                        | Rilpivirine    | 156                   | 156              | 0.38 (0.24;0.61)             | <0.001  | 0.33 (0.20;0.54)              | <0.001  |

(Continued)
In the present study, we had the unique opportunity to study the effectiveness of the most used HIV treatments in an entire national real world HIV cohort. Second, in a randomized clinical trial, the physician is excluded from using their clinical expertise to individualize the treatment according to patient characteristics. For example, in several clinical studies, efavirenz has been shown to have CNS side effects leading to drug discontinuation in a significant number of patients [14–16]. In the clinical setting, the physician can decrease the risk for discontinuations by not using efavirenz in patients with factors known to increase the risk for neuropsychiatric side effects [17–19].

Third, a real world cohort gives the possibility to have a significantly longer observation period than in prospective clinical studies. In this study, we followed patients up to 6 years which rarely occurs in a clinical trial.

The overall treatment discontinuation rate in this study was similar for treatment naive and treatment experienced patients; 10% of the patients discontinued the 3rd agent within 3 months and a quarter within one year. However, the differences between drugs were

---

**Table 4. (Continued)**

| Covariate      | Value   | Distinct Patients (n) | Observations (n) | HR (95% CI) univariate model | P-value | HR (95% CI) multivariate model* | P-value |
|----------------|---------|-----------------------|------------------|-----------------------------|---------|-------------------------------|---------|
| Lopinavir      | 292     | 292                   | 3.23 (2.76;3.79) | <0.001                      | 2.80 (2.30;3.40) | <0.001                        |
| Atazanavir     | 386     | 386                   | 1.08 (0.90;1.29) | 0.416                       | 1.06 (0.88;1.29) | 0.528                         |
| Darunavir      | 504     | 504                   | 1.07 (0.89;1.28) | 0.467                       | 0.94 (0.77;1.14) | 0.516                         |
| Raltegravir    | 149     | 149                   | 1.85 (1.45;2.37) | <0.001                      | 1.47 (1.12;1.92) | 0.005                         |

* Adjustments made for treatment, age, gender, region of birth, CD4 count at baseline, viral load at baseline, CDC class, route of infection, year of initiation treatment, hepatitis status, N[T]RTI backbone treatment.

---

**Fig 2. Risk for treatment discontinuation in treatment-experienced patients (Treatment effects showing Hazard Ratios from univariate and multivariate Cox regression models).**

do:10.1371/journal.pone.0171227.g002
Table 5. Hazard Ratios from univariate and multivariate Cox regression models for treatment-experienced patients.

| Covariate                      | Value       | Distinct Patients (n) | Observations (n) | HR (95% CI) univariate model | P-value | HR (95% CI) multivariate model | P-value |
|--------------------------------|-------------|-----------------------|------------------|-----------------------------|---------|-------------------------------|---------|
| Age                            | Age <50     | 2081                  | 3144             | 0.95 (0.86;1.05)             | 0.308   | 0.97 (0.87;1.08)              | 0.561   |
|                                | Age ≥50     | 951                   | 1403             | 0.73 (0.18;2.93)             | 0.660   | 0.42 (0.10;1.68)              | 0.219   |
|                                | Missing     | 3                     | 5                | Reference                    |         | Reference                      |         |
| NRTI Backbone                  | No Backbone | 211                   | 356              | 0.84 (0.70;1.01)             | 0.067   | 0.81 (0.66;0.99)              | 0.038   |
| ABC/3TC                        | 1046        | 1376                  | 1.06 (0.96;1.17)  | 0.253                        |         | 1.09 (0.98;1.21)              | 0.128   |
| TDF/FTC                        | 1807        | 2463                  | Reference        | Reference                    |         |                               |         |
| Other                          | 275         | 357                   | 1.39 (1.19;1.63)  | <0.001                       |         | 1.21 (1.02;1.43)              | 0.026   |
| CD4 cell count at baseline     | ≤200        | 414                   | 606              | 1.64 (1.44;1.88)             | <0.001  | 1.27 (1.08;1.49)              | 0.004   |
|                                | 201–350     | 732                   | 944              | 1.29 (1.14;1.46)             | <0.001  | 1.00 (0.87;1.14)              | 0.978   |
|                                | 351–500     | 826                   | 992              | 1.06 (0.93;1.20)             | 0.393   | 0.96 (0.84;1.09)              | 0.495   |
|                                | >500        | 1236                  | 1606             | Reference                    |         | Reference                      |         |
| CDC Class                      | C/AIDS      | 520                   | 823              | 1.06 (0.95;1.19)             | 0.285   | 1.03 (0.91;1.16)              | 0.630   |
|                                | Non-C (i.e. A or B) | 2482           | 3729             | Reference                    |         | Reference                      |         |
| Region of birth                | Sweden      | 1190                  | 1816             | Reference                    |         | Reference                      |         |
|                                | Western Europe, USA, Israel, Canada, North Africa, Middle East | 381  | 576 | 1.01 (0.88;1.17) | 0.858 | 1.07 (0.92;1.24) | 0.363 |
|                                | Africa (East, South, West and Central) | 1024 | 1598 | 1.02 (0.92;1.13) | 0.722 | 0.97 (0.84;1.12) | 0.652 |
|                                | Eastern Europe, Asia, Pacific, Caribbean, Latin America | 363 | 521 | 0.82 (0.69;0.96) | 0.013 | 0.74 (0.62;0.88) | <0.001 |
|                                | Missing     | 358                   | 404              | 1.06 (0.88;1.27)             | 0.530   | 1.01 (0.83;1.24)              | 0.898   |
| Gender                         | Male        | 1779                  | 2651             | Reference                    |         | Reference                      |         |
|                                | Female      | 1212                  | 1901             | 1.13 (1.03;1.24)             | 0.007   | 1.14 (1.01;1.29)              | 0.030   |
| Hepatitis Status               | Negative    | 2795                  | 4241             | Reference                    |         | Reference                      |         |
|                                | Hep B seropositive | 61  | 6  | 0.74 (0.52;1.07) | 0.108 | 0.81 (0.56;1.17) | 0.266 |
|                                | Hep C seropositive | 134 | 213 | 1.30 (1.07;1.58) | 0.009 | 1.03 (0.82;1.29) | 0.788 |
|                                | Hep B+C seropositive | 6  | 12 | 1.87 (0.93;3.74) | 0.078 | 1.58 (0.78;3.20) | 0.204 |
| Transmission Route             | Heterosexual | 1550         | 2357             | 1.06 (0.95;1.17)             | 0.286   | 0.86 (0.74;0.99)              | 0.039   |
|                                | MSM         | 960                   | 1454             | Reference                    |         | 0.62 (0.41;0.94)              | 0.023   |
|                                | IVDU        | 220                   | 358              | 1.60 (1.36;1.88)             | <0.001  | 1.20 (0.99;1.46)              | 0.066   |
|                                | Other/unknown | 233 | 353 | 1.09 (0.91;1.31) | 0.357 | 0.88 (0.72;1.09) | 0.242 |
|                                | Missing     | 28                    | 30               | 0.74 (0.35;1.55)             | 0.424   | 0.61 (0.28;1.30)              | 0.199   |
| Treatment Start Year           | 2009–2010   | 1309                  | 1654             | Reference                    |         | Reference                      |         |
|                                | 2011–2012   | 1286                  | 1617             | 0.95 (0.86;1.05)             | 0.319   | 1.23 (1.11;1.37)              | <0.001  |
|                                | 2013–2014   | 1084                  | 1281             | 0.83 (0.72;0.95)             | 0.006   | 1.32 (1.14;1.53)              | <0.001  |
| Line of Therapy                | 1†         | 66                    | 66               | 0.82 (0.54;1.23)             | 0.331   | 0.62 (0.41;0.94)              | 0.023   |
|                                | 2           | 1647                  | 1647             | Reference                    |         | Reference                      |         |
|                                | 3           | 1057                  | 1057             | 0.98 (0.87;1.11)             | 0.752   | 1.09 (0.96;1.24)              | 0.169   |
|                                | 4+          | 1119                  | 1782             | 1.09 (0.98;1.21)             | 0.113   | 1.37 (1.19;1.56)              | <0.001  |
| Baseline Viral Load            | <50         | 2021                  | 2613             | Reference                    |         | Reference                      |         |
|                                | 51–1,000    | 517                   | 658              | 1.37 (1.20;1.56)             | <0.001  | 1.25 (1.09;1.44)              | 0.001   |
|                                | 1,001–10,000 | 267           | 338             | 1.83 (1.56;2.14)             | <0.001  | 1.59 (1.34;1.88)              | <0.001  |
|                                | 10,001–100,000 | 408             | 512             | 1.49 (1.30;1.72)             | <0.001  | 1.21 (1.04;1.41)              | 0.014   |
|                                | >100,000    | 226                   | 291              | 1.92 (1.63;2.26)             | <0.001  | 1.46 (1.21;1.75)              | <0.001  |

(Continued)
significant with discontinuation rates one year after start of treatment of more than 50% in lopinavir patients compared to approximately 10% in rilpivirine patients. It is also noticeable that different drugs in the same class of drugs can perform very differently. This indicates that comparisons between classes of HIV drugs do not take into account the specific characteristics of the individual ARVs and therefore can be misleading.

We found that the selection of a 3rd agent seemed to have a stronger influence on treatment duration than demographic or clinical factors. Both in treatment-naive and treatment-experienced patients, rilpivirine had a significantly lower risk for early treatment discontinuation compared to the other drugs studied. There may be several factors contributing to this. In treatment-naive patients starting on rilpivirine very few had an HIV-RNA > 100 000 copies/ml at start of treatment confirming its use according to label, very few had low CD4 cell counts and none of the patients had an AIDS diagnosis. In treatment-experienced patients starting rilpivirine a high proportion, 87% of the patients, had a viral load below 50 copies/ml at baseline indicating that the main reasons for switch were tolerability issues or simplification. Both in treatment-naive and treatment-experienced analyses rilpivirine still had a significantly lower risk of discontinuation when adjusted for these factors but it is still not possible to rule out an unmeasured bias e.g. the prescribing physicians estimation of the patient adherence level. Our interpretation is that the superiority shown for rilpivirine is partly due to channeling bias where rilpivirine was chosen for being easy to treat patients with an anticipated good adherence, but its favorable side effect profile shown in phase 3 studies also was a contributing factor [20,21].

Both in treatment-naive and in treatment-experienced patients starting lopinavir, there was a significant higher risk for early treatment discontinuation compared to all other drugs studied. A plausible explanation is that early in the study period lopinavir was no longer recommended in the Swedish HIV treatment guidelines because of its less favorable gastro-intestinal side effect profile and its more pronounced negative effect on blood lipids compared to the two other recommended protease inhibitors darunavir and atazanavir [11]. Together with the need for twice daily dosing this may have accelerated the switch rate from lopinavir. Also, a relatively high proportion of patients, 40% of naive and 24% of treatment-experienced who used

| Covariate | Value | Distinct Patients (n) | Observations (n) | HR (95% CI) univariate model | P-value | HR (95% CI) multivariate model* | P-value |
|-----------|-------|-----------------------|-----------------|----------------------------|---------|-------------------------------|---------|
| Missing  | 124   | 140                   | 1.26 (0.98;1.63) | 0.073                      | 1.00 (0.76;1.33) | 0.973                                      |
| 3rd Agent | Efavirenz | 668                 | 694             | 1.51 (1.30;1.74)         | <0.001  | 1.86 (1.59;2.17)               | <0.001  |
|          | Etravirine | 243                 | 262             | 1.53 (1.26;1.87)         | <0.001  | 1.61 (1.31;1.98)               | <0.001  |
|          | Rilpivirine | 584              | 592             | 0.60 (0.48;0.74)         | <0.001  | 0.66 (0.52;0.83)               | <0.001  |
|          | Lopinavir | 271                 | 291             | 3.42 (2.92;4.01)         | <0.001  | 3.58 (3.02;4.25)               | <0.001  |
|          | Atazanavir | 720               | 806             | 1.54 (1.35;1.77)         | <0.001  | 1.71 (1.48;1.97)               | <0.001  |
|          | Darunavir | 1200              | 1285            | Reference                |          | Reference                      |         |
|          | Raltegravir | 594              | 622             | 1.29 (1.10;1.51)         | 0.001   | 1.35 (1.15;1.58)               | <0.001  |
| Years Since Start of first ART | 0–2 years | 1062               | 1413            | Reference                |          | Reference                      |         |
|          | 3–5 years | 535                 | 623             | 0.87 (0.75;1.00)         | 0.057   | 0.87 (0.75;1.02)               | 0.078   |
|          | 5+ years | 1668                | 2516            | 0.85 (0.77;0.94)         | 0.002   | 0.78 (0.68;0.88)               | <0.001  |

* Adjustments made for treatment, age, gender, ethnicity, CD4 count at treatment baseline, viral load at baseline, year of initiation treatment, years since start 1st treatment, line of therapy, hepatitis status, and N[t]RTI Backbone treatment.
†Patients with a prior treatment episode with only N[t]RTIs and starting their first treatment including a 3rd agent during the study period 2009–2014

doi:10.1371/journal.pone.0171227.t005
lopinavir did not use or tenofovir disoproxil fumarate/emtricitabine as N[t]RTI backbone treatment, but other (older) combinations which may have further contributed to the poorer result seen. The high use of other backbone combinations may in part be explained by more women taking lopinavir indicating usage during pregnancy.

Treatment durations for efavirenz, darunavir and atazanavir were similar in treatment-naive patients but raltegravir had a significantly higher risk of early treatment discontinuation. In the STARTMRK study patients on raltegravir had significantly fewer drug related adverse events than patients on efavirenz [22]. In our present study naive patients starting efavirenz showed lower risk for early drug discontinuation compared to raltegravir. One explanation may be that physicians followed the recommendation in Swedish treatment guidelines not to initiate efavirenz treatment in patients with psychiatric problems thereby avoiding some treatment discontinuations due to neuropsychiatric adverse events.

In treatment-experienced patients darunavir, the most commonly used 3rd agent during our study period, showed a significantly lower risk for treatment discontinuation than all other ARVs, except for rilpivirine. In line with clinical trials results our interpretation is that this is a reflection of its favorable side effect profile, compared to other boosted protease inhibitors, together with high efficacy and low risk for resistance development across different patient types [23, 24]. In treatment-experienced patients a high genetic barrier and a low risk for resistance development is of importance if the switch is because of previous treatment failure or sub-optimal adherence [25, 26].

In line with other reports this study confirms that, besides the ARV chosen, certain baseline characteristics of patients are independently associated with differences in treatment duration [27–30]. In naive patients we found that AIDS diagnosis and the use of other backbone than ABC/3TC or TDF/FTC increased the risk for early treatment discontinuation. Heterosexual transmission category decreased the risk in comparison to MSM. In treatment-experienced patients, indicators of viral failure or a highly treatment experienced patient increased the risk for early treatment discontinuation; CD4 cell count <200, use of other backbone than ABC/3TC or TDF/FTC, being on 4th or higher line of treatment or having viral load >50 copies ml at start of treatment. In both treatment-naive and treatment-experienced patients, a start of treatment in 2011 or later was correlated to an earlier treatment discontinuation. One possible explanation is that in this time period we had a higher switch rate from older drugs like lopinavir and newer drugs like rilpivirine, elvitegravir and dolutegravir were introduced.

There are several limitations with our study the most important being that we cannot provide the reasons for drug discontinuations. Both viral failure with development of resistance associated mutations and some drug toxicities may limit future treatment options while this is not the case in treatment modifications to lower pill burden or to have less frequent dosing.

We also did not have any data on the level of adherence. Neither measurements of adherence nor physician’s estimates of adherence were available. Estimated or observed adherence probably has an important impact on the choice of new treatment regimens. Another limitation is that not all kinds of data are included in InfCareHIV. It would have been of interest to see e.g. how socioeconomic factors like education, employment, income, marital status, active drug use influence drug duration time.

Last, the data and the results are mostly applicable to the time period studied and to Sweden or other countries with a similar health care environment. Sweden is a country with a low HIV prevalence, and the care of HIV patients in Sweden is highly specialized; all HIV infected patients are linked to specialized HIV care centers with dedicated multidisciplinary teams of physicians, nurses and social workers, Following the Swedish law of Communicable Disease Act all HIV drugs and HIV health care are freely available for patients but also obliges the patients to keep regular contact with the responsible HIV clinic. All this are contributing to the
excellent treatment outcomes in Swedish HIV patients, and we believe Sweden is the first country to achieve the UNAIDS/WHO 90-90-90 targets [31].

In conclusion, we found that selection of the 3rd agent is an important factor to maximize treatment duration. The choice of backbone, ABC/3TC or TDF/FTC, had no effect on 3rd agent duration. Individualizing treatment can avoid some toxicity discontinuations, e.g. efavirenz and CNS side effects. Use of rilpivirine in naïve patients is associated with long treatment duration if use in patients with high viral load or advanced disease is avoided. The same applies to treatment-experienced patients who switch to rilpivirine with undetectable viral load. In treatment-experienced patients darunavir was the mostly used drug and, besides rilpivirine, also showed the lowest risk for treatment discontinuation.

Author Contributions
Conceptualization: SL MG VS SV.
Data curation: SL VS.
Formal analysis: AH EH.
Investigation: AH MG BH LF VS.
Methodology: SL MG VS AH SV AL AP.
Project administration: SL VS.
Resources: AH MG LF BH VS.
Software: AL EH.
Supervision: VS.
Validation: SL VS EH.
Visualization: EH LF.
Writing – original draft: AH AP.
Writing – review & editing: AH MG LF BH VS AP.

References
1. Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C et al. The effect of combined antiretroviral therapy on the overall mortality of HIV infected individuals. AIDS 2010; 24:123–137. doi: 10.1097/QAD.0b013e32832f903b PMID: 19770621
2. Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, et al. Transmission of HIV drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. Clin Infect Dis. 2016 Mar 1; 62 (5):655–63. doi: 10.1093/cid/civ963 PMID: 26620852
3. Ortego C, Huedo-Medin TB, Llorca J, Sevilla L, Santos P, Rodríguez E, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011; 15:1381–964. doi: 10.1007/s10461-011-9942-x PMID: 21468860
4. University of Liverpool HIV Drug Interaction Website. Available from: http://www.hiv-druginteractions.org/
5. The Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Available from: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/31/adverse-effects-of-arv
6. Prosperi MC, Fabbiani M, Fanti I, Zaccarelli M, Colafiglia M, Mondi A, et al. Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infect Dis. 2012 Nov 12; 12:296. doi: 10.1186/1471-2334-12-296 PMID: 23145925
7. Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representiveness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015; 16:495. doi: 10.1186/s13063-015-1023-4 PMID: 26530985

8. Marrone G, Meilgren Å, Eriksson LE, Svedhem V. High Concordance between Self-Reported Adherence, Treatment Outcome and Satisfaction with Care Using a Nine-Item Health Questionnaire in InfCareHIV. PLoS One. 2016 Jun 16; 11(6):e0156916. doi: 10.1371/journal.pone.0156916 PMID: 27310201

9. Josephson F, Albert J, Flamholc L, Gisslen M, Karlström O, Moberg L, et al. Treatment of HIV infection: Swedish recommendations 2009. Scand J Infect Dis 2009, 41:788–807. doi: 10.3109/00365540903214322 PMID: 19922061

10. Naver L, Albert J, Belfrage E, Flamholc L, Gisslen M, Gyllensten K, et al. Swedish Reference Group for Antiviral Therapy. Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2010. Scand J Infect Dis. 2011 Jul; 43(6–7):411–23. doi: 10.3109/00365548.2011.567392 PMID: 21438788

11. Antiretroviral behandling av HIV infektion–uppdaterad rekommendation. Information från läkemedelsverket 3:2011 s 8–35. Avvald från: https://lakemedelsverket.se/overgripande/Publikationer/Periodiska-utgavor/Information-fran-Lakemedelsverket/ (in Swedish)

12. Antiretroviral behandling av HIV-infektion-uppdaterad rekommendation. Avvald från: http://www.sils.se/Global/RAV/Dokument/RAV_HIV_2014_final_141114.pdf (In Swedish)

13. Eriksen J, Albert J, Blaxhult A, Carlander C, Flamholc L, Gisslen M, et al. Antiretroviral treatment for HIV infection; Swedish recommendations 2016. Infectious Dis (Lond), 2016 Nov 2;1–34 (Epub2016 Nov 2.

14. Mills AM, Antinori A, Ciotet B, Fourie J, Herrera G, Hicks C, et al. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks. HIV Med. 2013 Aug; 14(7):391–400. doi: 10.1111/hiv.12012 PMID: 23299380

15. Leutscher PD, Stecher C, Storgaard M, Larsen CS. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. Scand J Infect Dis. 2013 Aug; 45(8):645–51. doi: 10.3109/00365548.2013.773067 PMID: 23427878

16. Pérez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials 2002; 3: 279–86. doi: 10.1310/hct.2002.3.4.003 PMID: 12187501

17. Blanch J, Martínez E, Rousaud A, Blanco JL, García-Viejo MA, Peri JM, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr 2001; 27:336–43. PMID: 11468421

18. Spire B, Carriere P, Garzot MA, L’henaff M, Obadia Y; TRT-5 Group. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care. 2004; 16:558–64. doi: 10.1080/09540120410001716342 PMID: 15223524

19. Gutiérrez F, Navarro A, Padilla S, Antón R, Masía M, Borrás J, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005; 40:1648–53. doi: 10.1086/497835 PMID: 16267739

20. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. Rilpivirine versus efavirenz and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378: 238–46. doi: 10.1016/S0140-6736(11)60936-7 PMID: 21763936

21. Cohen CJ, Andrade-Villanueva J, Ciotet B, Fourie J, Johnson MA, Ruxrungtham K, et al. Rilpivirine versus efavirenz with two backbone nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378: 229–37. doi: 10.1016/S0140-6736(11)60935-5 PMID: 21763935

22. Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Han W, et al. STARTMRK Investigators. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013 May 1; 63(1):77–85. doi: 10.1097/QAI.0b013e31828ace68 PMID: 23412015

23. Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naïve, HIV-1-infected patients: 96-week analysis. AIDS. 2009 Aug 24; 23(13):1679–88. doi: 10.1097/QAD.0b013e328327d350 PMID: 19487905

24. Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, et al; ACTG A5257 Team. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naïve volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 7; 161(7):461–71. doi: 10.7326/M14-1084 PMID: 25285539
25. De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T, et al. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS. 2009 Sep 10; 23(14):1829–40. doi: 10.1097/QAD.0b013e32832cbbec PMID: 19474650

26. Nelson M, Girard PM, Demasi R, Chen L, Smets E, Sekar V, et al. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data. J Antimicrob Chemother. 2010 Jul; 65(7):1505–9. doi: 10.1093/jac/dkq150 PMID: 20498120

27. Antiretroviral Therapy Cohort Collaboration. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009. AIDS. 2013; 27(5):803–13. doi: 10.1097/QAD.0b013e32835cb997 PMID: 23719350

28. Di Biagio A, Cozzi-Lepri A, Prinapori R, Angarano G, Gori A, Quirino T, et al. Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort. J Int AIDS Soc 2014, 17:19825. doi: 10.7448/IJAS.17.4.19825 PMID: 25397569

29. Sheth AN, Ofotokun I, Buchacz K, Armon C, Chmiel JS, Hart RL, et al. Antiretroviral Regimen Durability and Success in Treatment-Naive and Treatment-Experienced Patients by Year of Treatment Initiation, United States, 1996–2011. J Acquir Immune Defic Syndr. 2016 Jan 1; 71(1):47–56. doi: 10.1097/QAI.0000000000000813 PMID: 26334737

30. Kowalska JD, Kubicka J, Siwak E, Pullik P, Florag-Burkacka E, Horban A, et al. Factors associated with the first antiretroviral therapy modification in older HIV-1 positive patients. AIDS Research and Therapy. 2016; 13:2. doi: 10.1186/s12981-015-0084-5 PMID: 26744599

31. Gisslen M, Svedhem V, Lindborg L, Flamholc L, Norr gren H, Wendahl S, et al. Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90-90-90 continuum of HIV care targets. HIV Med. 2016 Aug 18. doi: 10.1111/hiv.12431